Home pageLXRX • NASDAQ
add
Lexicon Pharmaceuticals
2,39Â $
After Hours:(0,42%)+0,0100
2,40Â $
Data e ora chiusura: 26 lug, 18:18:34 GMT-4 · USD · NASDAQ · Disclaimer
Chiusura precedente
2,33Â $
Intervallo giornaliero
2,32Â $ - 2,44Â $
Intervallo annuale
0,92Â $ - 3,73Â $
Cap di mercato
863,85Â Mln USD
Volume medio
3,01Â Mln
Rapporto P/E
-
Dividendo/Prezzo
-
Borsa valori principale
NASDAQ
Notizie
Dati finanziari
Conto economico
Entrate
Utile netto
(USD) | mar 2024info | Variazione Y/Y |
---|---|---|
Entrate | 1,13Â Mln | 4.608,33% |
Spese di gestione | 32,06Â Mln | 67,50% |
Utile netto | -48,40Â Mln | -51,55% |
Margine di profitto netto | -4282,92 | 96,78% |
Utili per azione | -0,20 | -17,65% |
EBITDA | -45,19Â Mln | -45,63% |
Aliquota fiscale effettiva | — | — |
Stato patrimoniale
Totale attivo
Totale passivo
(USD) | mar 2024info | Variazione Y/Y |
---|---|---|
Investimenti cash/breve termine | 355,60Â Mln | 235,67% |
Totale attivo | 417,22Â Mln | 156,41% |
Totale passivo | 128,35Â Mln | 71,89% |
Patrimonio netto totale | 288,87 Mln | — |
Azioni in circolazione | 246,24 Mln | — |
Prezzo/valore contabile | 1,99 | — |
Redditività dell'attivo | -35,05% | — |
Rendimento sul capitale | -38,14% | — |
Flusso di cassa
Flusso di cassa netto
(USD) | mar 2024info | Variazione Y/Y |
---|---|---|
Utile netto | -48,40Â Mln | -51,55% |
Liquidità di esercizio | -55,13 Mln | -74,39% |
Contanti da investimenti | -110,22Â Mln | -1.011,47% |
Contanti da finanziamenti | 239,38Â Mln | 29.151,33% |
Flusso di cassa netto | 74,03Â Mln | 463,89% |
Flusso di cassa libero | -37,14Â Mln | -77,19% |
Informazioni
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company developing treatments for human disease. The company was founded in 1995 in The Woodlands, Texas under the name Lexicon Genetics, Incorporated by co-founders Professor Allan Bradley, FRS and Professor Bradley's postdoctoral fellow Arthur T Sands. The company has used its patented mouse gene knockout technology and extensive in vivo screening capabilities to study nearly 5,000 genes in its Genome5000 program and has identified over 100 potential therapeutic targets. Lexicon has advanced multiple drug candidates into human clinical trials and has a broad and diverse pipeline of drug targets behind its clinical programs. Lexicon is pursuing drug targets in five therapeutic areas including oncology, gastroenterology, immunology, metabolism, and ophthalmology.
The company's clinical drug candidates include sotagliflozin for the treatment of type 2 diabetes; LX1033 for the treatment of irritable bowel syndrome and other gastrointestinal disorders; telotristat ethyl for the treatment of the symptoms associated with carcinoid syndrome; and LX2931 for the treatment of autoimmune diseases, such as rheumatoid arthritis. Wikipedia
CEO
Fondazione
1995
Sito web
Dipendenti
285